Risi, Emanuela http://orcid.org/0000-0002-9307-9760
Grilli, Andrea
Migliaccio, Ilenia
Biagioni, Chiara
McCartney, Amelia
Guarducci, Cristina
Bonechi, Martina
Benelli, Matteo
Vitale, Stefania
Biganzoli, Laura
Bicciato, Silvio
Di Leo, Angelo
Malorni, Luca
Funding for this research was provided by:
Associazione Italiana per la Ricerca sul Cancro (my first AIRC grant (MFAG) 18880, AIRC Special Program Molecular Clinical Oncology “5 per mille”)
Breast Cancer Research Fondation
Fondazione Sandro Pitigliani
Article History
Received: 14 February 2018
Accepted: 17 March 2018
First Online: 22 March 2018
Compliance with ethical standards
:
: A Di Leo is a consultant/advisory board member for AstraZeneca, Bayer, Eisai, Genomic Health, Ipsen, Lilly, Novartis, Pfizer, and Pierre Fabre. L. Malorni is a consultant for AstraZeneca and Pfizer. No potential conflicts of interest were disclosed by the other authors.